Effect of a Single High-Dose Vitamin D-3 on the Length of Hospital Stay of Severely 25-Hydroxyvitamin D-Deficient Patients with COVID-19

Author(s)

Murai, Igor H. ^[1] ; Fernandes, Alan L. ^[1] ; Antonangelo, Leila ^[2] ; Gualano, Bruno ^[1] ; Rodrigues Pereira, Rosa Maria ^[1]

Affiliation

^[1] Univ Sao Paulo, Fac Med FMUSP, Div Reumatol, Sao Paulo, SP - Brazil

^[2] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Div Patol Clin, Sao Paulo, SP - Brazil

• Document type: Journal article
• Source: Clinics; v. 76, 2021.
• Web of Science Citations: 1

Abstract

OBJECTIVES: In this ancillary analysis of a multicenter, double-blinded, randomized, placebo-controlled trial, we investigated the effect of a single high dose of vitamin D-3 on the length of hospital stay of patients with severe 25-hydroxyvitamin D deficiency and COVID-19. METHODS: The primary outcome was length of hospital stay, defined as the total number of days that patients remained hospitalized from the date of randomization until the date of hospital discharge. Secondary outcomes included serum levels of 25-hydroxyvitamin D, mortality during hospitalization, number of patients admitted to the intensive care unit, and number of patients who required mechanical ventilation. RESULTS: Thirty-two patients were included in the study. The mean (SD) age was 58.5 (15.6) years, body mass index was 30.8 (8.6) kg/m(2), and 25-hydroxyvitamin D level was 7.8 (1.6) ng/mL. No significant difference was observed in the median interquartile range of length of hospital stay between the vitamin D-3 group (6.0 {[}4.0- 18.0] days) versus placebo (9.5 {[}6.3-15.5] days) (log-rank p=0.74; hazard ratio, 1.13 {[}95% confidence interval (CI), 0.53-2.40]; p=0.76). Vitamin D-3 significantly increased serum 25-hydroxyvitamin D levels in the vitamin D-3 group compared with that in the placebo group (between-group difference, 23.9 ng/mL {[}95% CI, 17.7-30.1]; p<0.001). CONCLUSIONS: A dose of 200.000 IU of vitamin D-3 did not significantly reduce the length of hospital stay of patients with severe 25-hydroxyvitamin D deficiency and COVID-19. (AU)

• FAPESP's process: 20/11102-2 - Vitamin D supplementation in patients with COVID-19: randomized, double-blind and placebo controlled clinical trial
• Grantee: Alan Lins Fernandes
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• FAPESP's process: 19/24782-4 - Comparison of mechanisms of bone loss in patients undergoing Roux-en-Y gastric bypass or sleeve gastrectomy
• Grantee: Igor Hisashi Murai
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• FAPESP's process: 20/05752-4 - Vitamin D supplementation in patients with COVID-19: randomized, double-blind and placebo controlled clinical trial
• Grantee: Rosa Maria Rodrigues Pereira
• Support Opportunities: Regular Research Grants